Company news: Roche

Share this article:
Roche reported disappointing third-quarter sales as key cancer drugs Avastin, Rituxan and Herceptin underperformed. Avastin sales declined 24% in the third quarter, while Herceptin was down 12% and Rituxan sales slid 10%. That, coupled with currency exchange effects, caused the company to miss analyst expectations and trumped an upbeat pipeline report from the firm.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions